Zacks Reiterates Neutral Rating for Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals plc (NASDAQ:JAZZ)‘s stock had its “neutral” rating reiterated by Zacks in a research note issued on Monday, Analyst Ratings.Net reports. They currently have a $143.00 price objective on the stock. Zacks‘s price target would suggest a potential upside of 5.03% from the stock’s previous close.
Zacks’ analyst wrote, “Jazz’ fourth-quarter earnings of $1.56 per share were below the Zacks Consensus Estimate of $1.64 but above the year-ago earnings of $1.38. We are encouraged by the strong growth exhibited by key products Xyrem and Erwinaze. Both should continue performing well. We are also positive on Jazz’ efforts to boost sales through label expansions. We are positive on the Gentium acquisition. We believe the company will continue to pursue such deals to boost its product portfolio and pipeline. Meanwhile, the Xyrem patent litigation remains a matter of concern. We maintain a Neutral recommendation on the stock.”
In other Jazz Pharmaceuticals plc news, CMO Jeffrey Tobias sold 3,000 shares of Jazz Pharmaceuticals plc stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $128.54, for a total value of $385,620.00. Following the completion of the transaction, the chief marketing officer now directly owns 48,103 shares in the company, valued at approximately $6,183,160. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) traded up 0.22% on Monday, hitting $136.45. The stock had a trading volume of 335,796 shares. Jazz Pharmaceuticals plc has a 1-year low of $53.29 and a 1-year high of $176.60. The stock’s 50-day moving average is $143.6 and its 200-day moving average is $126.7. The company has a market cap of $7.923 billion and a P/E ratio of 38.79.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $1.72 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.78 by $0.06. The company had revenue of $235.80 million for the quarter, compared to the consensus estimate of $238.12 million. On average, analysts predict that Jazz Pharmaceuticals plc will post $8.20 earnings per share for the current fiscal year.
A number of other firms have also recently commented on JAZZ. Analysts at Canaccord Genuity initiated coverage on shares of Jazz Pharmaceuticals plc in a research note on Thursday. They set a “buy” rating and a $163.00 price target on the stock. Separately, analysts at Leerink Swann cut their price target on shares of Jazz Pharmaceuticals plc from $189.00 to $170.00 in a research note on Friday, March 28th. Finally, analysts at Barclays initiated coverage on shares of Jazz Pharmaceuticals plc in a research note on Friday, March 7th. They set an “overweight” rating and a $200.00 price target on the stock. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Jazz Pharmaceuticals plc has an average rating of “Buy” and an average price target of $169.35.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.